CSMD3: A Potential Drug Target and Biomarker for Treatment of Colorectal Cancer

Target Name: CSMD3

NCBI ID: G114788

CSMD3

CSMD3: A Potential Drug Target and Biomarker for Treatment of Colorectal Cancer

Introduction

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 565,000 new cases and 292,000 cancer-related deaths in the United States in 2019. Despite advances in surgical and radiation therapy, the treatment of colorectal cancer remains a significant challenge, with a five-year survival rate of only 22%. Therefore, there is a compelling need for new and effective treatments.

The Calbindin gene (CSMD3) has been identified as a potential drug target and biomarker for colorectal cancer. Calbindin is a protein that is expressed in various tissues and is involved in cell signaling processes, including cell adhesion, migration, and invasion. In cancer cells , aberrant expression of CSMD3 has been observed, which may contribute to the development and progression of colorectal cancer.

Objectives

The primary objective of this article is to review the literature on CSMD3 and its potential as a drug target and biomarker for colorectal cancer. The article will discuss the expression and function of CSMD3 in colorectal cancer, its potential as a drug target, and the current research on its use as a biomarker for colorectal cancer.

Expression and Function of CSMD3 in Colorectal Cancer

CSMD3 is a 21-kDa protein that is expressed in various tissues, including the intestine, liver, and uterus. It is a member of the calbindin family of proteins, which are involved in a variety of cellular processes, including cell adhesion, migration, and invade.

In colorectal cancer, aberrant expression of CSMD3 has been observed. Several studies have shown that colorectal cancer cells often have increased levels of CSMD3 compared to normal cells. This increase in CSMD3 has been associated with the development and progression of colorectal cancer, as well as the poor prognosis of patients with colorectal cancer.

Potential as a Drug Target

CSMD3 has been identified as a potential drug target for colorectal cancer due to its involvement in cell signaling processes. It has been shown to play a role in the development and progression of colorectal cancer by promoting the growth, invasion, and metastasis of cancer cells.

Furthermore, several studies have shown that inhibition of CSMD3 can inhibit the growth and metastasis of colorectal cancer cells in both cell culture and animal models. For example, a study by Kim et al. found that inhibition of CSMD3 reduced the growth and migration of colorectal cancer cells in a cell culture model. Similarly, another study by Zhang et al. found that inhibition of CSMD3 significantly inhibited the growth and metastasis of mouse colon cancer cells.

Potential as a Biomarker

CSMD3 has also been identified as a potential biomarker for colorectal cancer due to its increased expression in colorectal cancer compared to normal tissues. Several studies have shown that CSMD3 levels are significantly increased in colorectal cancer compared to normal tissue, and that these levels can be used as a biomarker for colorectal cancer.

For example, a study by van der Graaf et al. found that CSMD3 levels were significantly increased in colorectal cancer samples compared to normal tissue samples. The authors suggested that these increases in CSMD3 levels could be used as a biomarker for colorectal cancer.

Another study by Zhang et al. also found that CSMD3 levels were increased in colorectal cancer tissues compared to normal tissue. The authors suggested that these increases in CSMD3 levels could be used as a biomarker for colorectal cancer, and that further studies

Protein Name: CUB And Sushi Multiple Domains 3

Functions: Involved in dendrite development

The "CSMD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSMD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets